EA202092953A1 - Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона - Google Patents
Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дионаInfo
- Publication number
- EA202092953A1 EA202092953A1 EA202092953A EA202092953A EA202092953A1 EA 202092953 A1 EA202092953 A1 EA 202092953A1 EA 202092953 A EA202092953 A EA 202092953A EA 202092953 A EA202092953 A EA 202092953A EA 202092953 A1 EA202092953 A1 EA 202092953A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- patient
- thiazolidine
- dione
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к способам лечения заболевания или нарушения у пациента, включающим введение 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона ("соединение (1)") или его фармацевтически приемлемой соли пациенту, где пациент достигает пороговой концентрации в стационарном состоянии для соединения (1). Настоящее изобретение также относится к способам введения терапевтически эффективного количества соединения (1) или его фармацевтически приемлемой соли пациенту. Соединение (1) представляет собой агонист PPAR-, который используют для лечения различных заболеваний и нарушений, включая, но не ограничиваясь ими, неалкогольный стеатогепатит и заболевания центральной нервной системы, например Х-сцепленную адренолейкодистрофию, атаксию Фридрейха.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382398 | 2018-06-06 | ||
PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092953A1 true EA202092953A1 (ru) | 2021-04-12 |
Family
ID=62716009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092953A EA202092953A1 (ru) | 2018-06-06 | 2019-06-06 | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210308113A1 (ru) |
EP (1) | EP3801516A1 (ru) |
JP (1) | JP2021527045A (ru) |
KR (1) | KR20210031435A (ru) |
CN (1) | CN112512524A (ru) |
AU (1) | AU2019283649A1 (ru) |
BR (1) | BR112020024917A2 (ru) |
CA (1) | CA3102407A1 (ru) |
CL (1) | CL2020003162A1 (ru) |
EA (1) | EA202092953A1 (ru) |
IL (1) | IL279183A (ru) |
MX (1) | MX2020013181A (ru) |
SG (1) | SG11202012045UA (ru) |
WO (1) | WO2019234689A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019234664A1 (en) | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2630604C (en) * | 2005-11-29 | 2016-01-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
ES2678046T3 (es) * | 2014-04-02 | 2018-08-08 | Minoryx Therapeutics S.L. | Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central |
SI3559010T1 (sl) | 2016-12-23 | 2022-10-28 | Minoryx Therapeutics S. L. | Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega |
-
2019
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en unknown
- 2019-06-06 JP JP2020567799A patent/JP2021527045A/ja active Pending
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko unknown
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt unknown
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en active Pending
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019234689A1 (en) | 2019-12-12 |
IL279183A (en) | 2021-01-31 |
CN112512524A (zh) | 2021-03-16 |
CA3102407A1 (en) | 2019-12-12 |
MX2020013181A (es) | 2021-02-26 |
AU2019283649A1 (en) | 2021-01-07 |
US20210308113A1 (en) | 2021-10-07 |
EP3801516A1 (en) | 2021-04-14 |
SG11202012045UA (en) | 2021-01-28 |
BR112020024917A2 (pt) | 2021-03-09 |
CL2020003162A1 (es) | 2021-07-02 |
KR20210031435A (ko) | 2021-03-19 |
JP2021527045A (ja) | 2021-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005536475A5 (ru) | ||
EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
CO2021002230A2 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
RU2010129272A (ru) | Производные аминотриазола в качестве агонистов alх | |
RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
US20190216804A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis | |
CN102770159A (zh) | Ep-4受体拮抗剂在治疗il-23介导疾病中的用途 | |
JP2007538064A (ja) | 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法 | |
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
JP2005506308A5 (ru) | ||
ES2938840T3 (es) | Uso de antagonistas del receptor EP4 en el tratamiento de enfermedad del cartílago | |
JP2015535247A5 (ru) | ||
RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
CN106999475B (zh) | 异噁唑啉化合物用于治疗蠕形螨病的用途 | |
JP2009532438A5 (ru) | ||
US9717727B2 (en) | Methods of treating and preventing leukemia and other cancers of the blood and bone | |
RU2008126389A (ru) | Производные 1,1- диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистаминаз(н3) | |
EA202092953A1 (ru) | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона | |
RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
Sharif | Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes | |
KR20080005526A (ko) | 가려움증의 치료 또는 예방 | |
BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca |